Literature DB >> 31035285

The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment.

Alan Chait1, Robert H Eckel2.   

Abstract

The chylomicronemia syndrome occurs when triglyceride levels are severely elevated (usually >16.95 mmol/L [1500 mg/dL]) and is characterized by such clinical features as abdominal pain, acute pancreatitis, eruptive xanthomas, and lipemia retinalis. It may result from 1 of 3 conditions: the presence of secondary forms of hypertriglyceridemia concurrent with genetic causes of hypertriglyceridemia, termed multifactorial chylomicronemia syndrome (MFCS); a deficiency in the enzyme lipoprotein lipase and some associated proteins, termed familial chylomicronemia syndrome (FCS); or familial partial lipodystrophy. Most chylomicronemia syndrome cases are the result of MFCS; FCS is very rare. In all these conditions, triglyceride-rich lipoproteins accumulate because of impaired plasma clearance. This review describes the 3 major causes of the chylomicronemia syndrome; their consequences; and the approaches to treatment, which differ considerably by group.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31035285     DOI: 10.7326/M19-0203

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  23 in total

Review 1.  Antisense technology: an overview and prospectus.

Authors:  Stanley T Crooke; Brenda F Baker; Rosanne M Crooke; Xue-Hai Liang
Journal:  Nat Rev Drug Discov       Date:  2021-03-24       Impact factor: 84.694

Review 2.  Chylomicronemia from GPIHBP1 autoantibodies.

Authors:  Kazuya Miyashita; Jens Lutz; Lisa C Hudgins; Dana Toib; Ambika P Ashraf; Wenxin Song; Masami Murakami; Katsuyuki Nakajima; Michael Ploug; Loren G Fong; Stephen G Young; Anne P Beigneux
Journal:  J Lipid Res       Date:  2020-09-18       Impact factor: 5.922

3.  Efficacy and safety of the apolipoprotein C-III inhibitor Volanesorsen: a systematic evaluation and meta-analysis.

Authors:  Yonglang Cheng; Tongxi Li; Peng Tan; Yichao Du; Zhiwei Huang; Hao Shi; Tianying Cai; Yifan Chen; Wenguang Fu
Journal:  Endocrine       Date:  2022-03-17       Impact factor: 3.633

4.  A protein of capillary endothelial cells, GPIHBP1, is crucial for plasma triglyceride metabolism.

Authors:  Stephen G Young; Wenxin Song; Ye Yang; Gabriel Birrane; Haibo Jiang; Anne P Beigneux; Michael Ploug; Loren G Fong
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-29       Impact factor: 12.779

5.  Chylomicronemia From GPIHBP1 Autoantibodies Successfully Treated With Rituximab: A Case Report.

Authors:  Jens Lutz; Malgorzata Dunaj-Kazmierowska; Sven Arcan; Ursula Kassner; Kazuya Miyashita; Masami Murakami; Michael Ploug; Loren G Fong; Stephen G Young; Katsuyuki Nakajima; Anne P Beigneux
Journal:  Ann Intern Med       Date:  2020-08-11       Impact factor: 25.391

6.  Intermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies.

Authors:  Ambika P Ashraf; Kazuya Miyashita; Katsuyuki Nakajima; Masami Murakami; Robert A Hegele; Michael Ploug; Loren G Fong; Stephen G Young; Anne P Beigneux
Journal:  J Clin Lipidol       Date:  2020-01-31       Impact factor: 4.766

7.  Dissection of Clinical and Gene Expression Signatures of Familial versus Multifactorial Chylomicronemia.

Authors:  Karine Tremblay; Daniel Gaudet; Etienne Khoury; Diane Brisson
Journal:  J Endocr Soc       Date:  2020-05-15

Review 8.  Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.

Authors:  Oluwayemisi Esan; Anthony S Wierzbicki
Journal:  Drug Des Devel Ther       Date:  2020-07-06       Impact factor: 4.162

Review 9.  Genetics of Hypertriglyceridemia.

Authors:  Jacqueline S Dron; Robert A Hegele
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-24       Impact factor: 5.555

10.  Genetic and functional studies of the LMF1 gene in Thai patients with severe hypertriglyceridemia.

Authors:  Wanee Plengpanich; Suwanna Muanpetch; Supannika Charoen; Arunrat Kiateprungvej; Weerapan Khovidhunkit
Journal:  Mol Genet Metab Rep       Date:  2020-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.